FDA Approves Merck's Welireg + Lenvima Combo in Advanced Kidney Cancer 10 Days Early

The FDA approved belzutifan (Welireg, Merck) in combination with lenvatinib (Lenvima, Eisai) on Sept 24 for adults with advanced renal cell carcinoma with a clear cell component (ccRCC) that progressed on or after a PD-1 or PD-L1 inhibitor. The decision landed 10 days ahead of the Oct 4 PDUFA date and rounds out Merck and Eisai’s HIF-2alpha franchise across three RCC settings.

The approval rests on LITESPARK-011, an open-label, randomized, active-controlled Phase 3 trial that assigned 747 patients 1:1 to belzutifan 120 mg plus lenvatinib 20 mg daily, or cabozantinib 60 mg daily. The combination cut the risk of progression or death by 26%, with median progression-free survival of 14.6 months versus 10.6 months for cabozantinib (hazard ratio 0.74, 95% CI 0.61-0.89; one-sided p=0.00095). The objective response rate was 53% versus 40%.

The survival result did not clear the bar. Median overall survival was 33.7 months versus 28.6 months (hazard ratio 0.85, 95% CI 0.70-1.03), which the FDA described as not statistically significant. That leaves open whether the combination extends life or only delays progression.

The approval is the first Phase 3 trial to beat cabozantinib head-to-head in the post-immunotherapy setting, where the drug had been the default second-line TKI after checkpoint failure.

Belzutifan remains the only approved HIF-2alpha inhibitor. It was first cleared as monotherapy in this setting in December 2023 and with pembrolizumab in the adjuvant setting in June 2026. The lenvatinib combination gives oncologists an all-oral, non-immunotherapy option after checkpoint failure. Our earlier PDUFA analysis lays out the trial detail and the competitive picture.

Safety tracks the known on-target effects of HIF-2alpha inhibition. The belzutifan label carries a boxed warning for embryo-fetal toxicity plus warnings for anemia and hypoxia; the combination adds a warning for cardiac dysfunction.

MRK closed at $147.98 on Sept 24, essentially flat on the news, consistent with Merck’s scale muting any single label catalyst.

What to watch: whether the OS trend firms up as data mature, and how the combination fares against Arcus’ casdatifan, the rival HIF-2alpha program still in Phase 3.

What It Means for the Trade

An approval ten days early on a drug already cleared as monotherapy in the same setting is not a headline catalyst for Merck, and the flat close at $147.98 confirms it. MRK is a mega-cap where the oncology story runs through Keytruda; Welireg plus Lenvima is franchise extension, priced accordingly. What the approval does change is the competitive clock for Arcus: casdatifan is still in Phase 3, while belzutifan now holds three approved RCC settings and a head-to-head win over cabozantinib that any challenger must beat or match. The actionable read is second-order: the HIF-2alpha class is validated against the post-immunotherapy standard of care, which raises the evidentiary bar for every readout in the space. The near-term watch items are the maturing survival data and label-driven uptake, since the combination gives oncologists a reason to pair belzutifan with lenvatinib instead of using the monotherapy.

Mechanism and Market Context

Belzutifan blocks HIF-2alpha, a transcription factor that clear-cell kidney tumors exploit by hijacking the cellular oxygen-sensing pathway. Where TKIs like cabozantinib choke tumor vasculature broadly and carry a familiar toxicity burden, HIF-2alpha inhibition is closer to a tumor-specific circuit breaker, which is why anemia and hypoxia are mechanism-inherent warnings rather than surprises. Lenvatinib, the VEGF-receptor TKI partner, adds vascular pressure from a second axis. The commercial backdrop matters: second-line ccRCC is a competitive but durable market, and an all-oral combination that beat cabozantinib head-to-head on progression-free survival (14.6 versus 10.6 months) and response rate (53% versus 40%) has a clean differentiation claim. Eisai shares the economics through the Lenvima partnership, which is why both companies frame this as one franchise across three settings.

Risks and What Could Go Wrong

1. The OS curve is unfinished business. A 0.85 hazard ratio with a confidence interval spanning 1.0 means the survival advantage may not hold, and oncologists increasingly demand overall survival evidence for premium positioning in RCC.
2. Subsequent-therapy confounding can distort survival comparisons as follow-up lengthens, and the PFS gap can narrow with longer observation.
3. Arcus’ casdatifan remains the swing factor for the class narrative; a stronger Phase 3 profile would pressure Welireg franchise growth assumptions.
4. The cardiac dysfunction warning added with the combination increases monitoring burden relative to monotherapy, which can slow adoption.

Source: FDA approval announcement